Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialIan Judson, Winette T.A. van der Graaf, Peter Hohenberger et al.|The Lancet Oncology|2014Cited by 1.2k
Multiple newly identified loci associated with prostate cancer susceptibilityDouglas F. Easton, Rosalind A. Eeles, Zsofia Kote‐Jarai et al.|Nature Genetics|2008Cited by 850
Can Patients With Relapsed, Previously Untreated, Stage I Epithelial Ovarian Cancer Be Successfully Treated With Salvage Therapy?Désirée Kolomainen, Martin Gore, Roger A’Hern et al.|Journal of Clinical Oncology|2003Cited by 34
Correspondence Re: O'Sullivan MJ, Kyriakos M, Zhu X, Wick MR, Swanson PE, Dehner LP, Humphrey PA, Pfeifer JD: Malignant Peripheral Nerve Sheath Tumors With T(X;18). A Pathologic and Molecular Genetic Study. Mod Pathol 2000;13:1336–46Marc Ladanyi, Jonathan A. Fletcher, James M. Woodruff et al.|Modern Pathology|2001Cited by 32
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancersG. Saturno, Caroline J. Springer, Filipa M. Lopes et al.|Annals of Oncology|2020Cited by 21